CN1391916A - Gastric ulcer treating capsule - Google Patents
Gastric ulcer treating capsule Download PDFInfo
- Publication number
- CN1391916A CN1391916A CN 01114102 CN01114102A CN1391916A CN 1391916 A CN1391916 A CN 1391916A CN 01114102 CN01114102 CN 01114102 CN 01114102 A CN01114102 A CN 01114102A CN 1391916 A CN1391916 A CN 1391916A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- gastric ulcer
- group
- procaine hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine capsule for treating gastric and duodenel ulcer, gastritis, gastraligia and acid stomach. The medicine has the functions of stopping pain, invigorating stomach, etc. The medicine capsule is prepared with cuttlebone, corydalis tuber, fritillary bulb, licorice extract, procaine hydrochloride and starch and through separate grinding, sieving, storing, crushing, mixing and capsulizing.
Description
The present invention relates to a kind of treatment stomach and duodenum, gastritis, the superacid medicine of stomachache stomach function regulating.
The Western medicine kind for the treatment of gastric ulcer in the market is a lot, Western medicine commonly used such as cimetidine, ranitidine, famotidine, Ah not are for fourth, bismuth potassium citrate and other medicine etc. of deriving, the common disadvantage of these medicines: toxic and side effects is too big, Liver and kidney there is infringement, women breast-feeding their children, the careful usefulness of anemia of pregnant woman or avoid usefulness, the H2 receptor blocking agent more has in various degree giddy, drowsiness, diarrhoea, feels sick, erythra etc., even the mental status such as disorientation, drowsiness, anxiety occur; Chinese patent medicine is also a lot, but the patient generally reacts the alleviating pain overlong time, acts on not obvious.
The object of the present invention is to provide treatment stomach that a kind of curative effect has no side effect again rapidly and duodenum, gastritis, the superacid medicine of stomachache stomach function regulating.
Task of the present invention realizes as follows: get 23.8～24.2 parts of Endoconcha Sepiaes, 3.8～4.2 parts of Rhizoma Corydalis (system), 3.4～3.8 parts of Bulbus Fritillariae Thunbergiis, 3.2～3.6 parts of Radix Glycyrrhizae extractum, procaine hydrochloride 0..8～1.2 part, starch is an amount of.The procaine hydrochloride porphyrize sieves, and Endoconcha Sepiae, Rhizoma Corydalis, Bulbus Fritillariae Thunbergii are ground into fine powder, and Radix Glycyrrhizae extractum oven dry is ground into fine powder, with above-mentioned medicated powder mix homogeneously, crosses 120 mesh sieves, incapsulates and forms every 0.35g.
Beneficial effect of the present invention: medicine of the present invention carries out clinical trial with the attached First Academy of Heilongjiang Province university of TCM, the Heilongjiang Province Fifth Academy of Aerospace Industry, the total institute of the People's Armed Police of Heilongjiang Province three tame provincial hospitals.Test objective: investigate leading position and the safety of its curative effect in similar drug, so set up matched group, the contrast medicine is selected eutherapeutic bismuth potassium citrate sheet for use, has observed 615 examples altogether, and medicine wherein of the present invention is observed 369 examples, and matched group is observed 246 examples.Result of the test shows: medicine of the present invention is taken safe and reliable, and is without any side effects, the effect that significant antacid, pain relieving are arranged, is good for the stomach.Determined curative effect is better than matched group.(for details see attached table 1～2) movable gastric ulcer of table 1 is treated Comparison of therapeutic (%) the gastroscope example number healing enabledisable after 4 weeks
82.93 97.56 2.44 treatment groups 369
(306/369)# (360/369)# (9/369)
68.29 78.05 21.95 matched groups 246
(168/246) # (192/246) # (54/246) #: two groups are compared P＜hungry belch acid regurgitation of 0.05 table 2 symptom example number abdominal pain and distension
97.22 91.89 97.06 95.63 treatment groups 369
(315/324)# (306/333)# (297/306) (241/252)#
81.08 75.68 96.77 87.50 matched groups 246
(180/222)# (168/222)# (180/186) (168/192)#
To stomachache, abdominal distention, two groups of significant differences of belch acid regurgitation (P＜0.05), to hungry two groups of zero differences.
Toxicity test: through animal acute toxicity test and long term toxicity test, this medicine is without any side effects.(for details see attached table 3～5)
Table 3 continuous use after 180 days the present invention to the influence of rat body weight change (g, X ± SD)
Different time (moon) body weight (g) after the body weight administration before the administration of group number of animals
(only) (g) 12
Blank 20 97.5 ± 5.5 175.5 ± 8.9 225.0 ± 8.5
Low dose group 20 98.8 ± 6.1 178.3 ± 6.9 230.9 ± 10.6
Middle dosage group 20 96.6 ± 4.9 177.1 ± 10.1 228.1 ± 9.7
High dose group 20 97.8 ± 7.2 174.4 ± 9.2 227.9 ± 7.6
Different time (moon) body weight (g) after the administration of group number of animals
(only) 3456
Blank 20 289.1 ± 9.9 315.4 ± 10.8 340.1 ± 12.0 385.7 ± 6.5
Low dose group 20 286.4 ± 7.1 310.9 ± 11.5 335.8 ± 8.9 382.3 ± 9.4
Middle dosage group 20 290.0 ± 11.5 312.1 ± 8.2 338.4 ± 11.1 379.9 ± 10.1
High dose group 20 288.4 ± 8.6 313.0 ± 9.0 333.9 ± 10.6 383.9 ± 7.7
Table 4 continuous use after 90 days the present invention to the hematological influence of rat (X ± SD)
Group number of animals RBC Hb WBC WBC classify (%)
(only) (* 10
12/ L) (g/L) (* 10
9/ L) LY GR
Blank 20 4.92 ± 0.46 131 ± 7.4 9.8 ± 3.7 69.2 ± 9.8 24.0 ± 7.1
Low dose group 20 4.81 ± 0.35 128 ± 6.9 8.83 ± 3.1 67.9 ± 5.1 23.1 ± 6.1
Middle dosage group 20 4.69 ± 0.40 123 ± 8.6 8.97 ± 2.8 68.6 ± 7.6 23.2 ± 6.7
High dose group 20 4.99 ± 0.50 132 ± 9.2 9.17 ± 2.8 66.1 ± 6.9 24.2 ± 5.2 table 5 continuous use after 90 days the present invention the rat blood biochemical is learned the influence (X ± SD) of index
Group number of animals BUN Grea SGPT SGOT ALB
(only) (mmol/L) (μ mol/L) (nmol/L) (nmol/L) (g/L)
Blank 20 6.5 ± 0.7 80.5 ± 9.5 69.1 ± 8.8 100.7 ± 13.9 34.8 ± 3.18
Low dose group 20 6.1 ± 0.9 79.1 ± 9.6 62.7 ± 11.2 104.5 ± 12.7 36.2 ± 5.0
Middle dosage group 20 6.3 ± 0.8 78.9 ± 9.4 65.7 ± 9.6 108.6 ± 12.8 33.3 ± 4.7
High dose group 20 6.3 ± 0.6 77.57 ± 8.7 63.1 ± 7.8 112.1 ± 12.5 34.1 ± 3.9
Pharmacodynamics test: pharmacodynamic experiment proves that " gastric ulcer treating capsule " can form the protective layer between ulcer surface and the gastric juice under one's belt rapidly, pain relieving, and hemostasis promotes the healing of ulcer surface.Can be in the back relieving spasm to stop pain in 5 to 10 minutes of taking medicine.(for details see attached table 6～9)
The influence of table 6 pair indometacin type ulcer model (X ± S)
Group number of animals ulcer level
Matched group 20 4.67 ± 0.28
*
Administration group 20 1.40 ± 0.45
*
*P＜0.01
The influence of table 7 pair ester acid type gastric ulcer model (X ± S)
Group number of animals ulcer level
Matched group 20 11.49 ± 1.15
Administration group 20 0.562 ± 0.258
*P＜0.01
The influence of table 8 pair stomach pyloric ligation ulcers gastric ulcer model (group number of animals total acidity gastric juice/mEg gastric activity/u ulcer grade matched group 20 38.11 ± 3.25 652.16 ± 74.09 5.36 ± 0.23 administration groups 20 22.02 ± 2.98 of X ± S)
*406.65 ± 44.93
*2.75 ± 0.57
* *P＜0.01
*P＜0.05
The influence of table 9 pair stress in rats gastric ulcer (X ± S)
Group number of animals ulcer level
Matched group 20 4.82 ± 0.22
*
Administration group 20 2.40 ± 0.69
*
*P＜0.01
A most preferred embodiment of the present invention is described in detail in detail below, gets Endoconcha Sepiae 24.2g, Rhizoma Corydalis (system) 3.8g, Bulbus Fritillariae Thunbergii 3.4g, Radix Glycyrrhizae extractum 3.2g, procaine hydrochloride 0.8g, starch is an amount of.The procaine hydrochloride porphyrize sieves, and Endoconcha Sepiae, Rhizoma Corydalis, Bulbus Fritillariae Thunbergii are ground into fine powder, and Radix Glycyrrhizae extractum oven dry is ground into fine powder, with above-mentioned medicated powder mix homogeneously, and packing, promptly.Every 0.35g of capsule, oral each 3～5, every day 3 times.
Second most preferred embodiment of the present invention got Endoconcha Sepiae 2 3.8g, Rhizoma Corydalis (system) 4.2g, Bulbus Fritillariae Thunbergii 3.8g, Radix Glycyrrhizae extractum 3.6g, procaine hydrochloride 1.2g, starch is an amount of.The procaine hydrochloride porphyrize sieves, and Endoconcha Sepiae, Rhizoma Corydalis, Bulbus Fritillariae Thunbergii are ground into fine powder, and Radix Glycyrrhizae extractum oven dry is ground into fine powder, with above-mentioned medicated powder mix homogeneously, and packing, promptly.Every 0.35g of capsule, oral each 3～5, every day 3 times.
Claims (1)
1, gastric ulcer treating capsule of the present invention, be a kind of treatment stomach and duodenum, gastritis, the superacid medicine of stomachache stomach function regulating, it is characterized in that: composition that drug formulation is contained and shared parts by weight are 23.8～24.2 parts of Endoconcha Sepiaes, 3.8～4.2 parts of Rhizoma Corydalis (system), 3.4～3.8 parts of Bulbus Fritillariae Thunbergiis, 3.2～3.6 parts of Radix Glycyrrhizae extractum, procaine hydrochloride 0..8～1.2 part, starch is an amount of, the procaine hydrochloride porphyrize, sieve, Endoconcha Sepiae, Rhizoma Corydalis, Bulbus Fritillariae Thunbergii is ground into fine powder, the Radix Glycyrrhizae extractum oven dry, be ground into fine powder, with above-mentioned medicated powder mix homogeneously, cross 120 mesh sieves, incapsulate and form every 0.35g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01114102 CN1391916A (en) | 2001-06-15 | 2001-06-15 | Gastric ulcer treating capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01114102 CN1391916A (en) | 2001-06-15 | 2001-06-15 | Gastric ulcer treating capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1391916A true CN1391916A (en) | 2003-01-22 |
Family
ID=4660780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01114102 Pending CN1391916A (en) | 2001-06-15 | 2001-06-15 | Gastric ulcer treating capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1391916A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100350947C (en) * | 2005-12-22 | 2007-11-28 | 陈宝贵 | Medicine for treating gastric and duodenal ulcer and preparing method |
| CN115137707A (en) * | 2022-09-02 | 2022-10-04 | 成都通德药业有限公司 | Compound procaine hydrochloride capsule and preparation method thereof |
-
2001
- 2001-06-15 CN CN 01114102 patent/CN1391916A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100350947C (en) * | 2005-12-22 | 2007-11-28 | 陈宝贵 | Medicine for treating gastric and duodenal ulcer and preparing method |
| CN115137707A (en) * | 2022-09-02 | 2022-10-04 | 成都通德药业有限公司 | Compound procaine hydrochloride capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1302800C (en) | Chinese traditional medicine preparation for curing gastric ulcer | |
| CN1391916A (en) | Gastric ulcer treating capsule | |
| CN1061552C (en) | Epilepsy recovering pill and preparing process thereof | |
| CN1055015C (en) | Weijisan for gastropathy | |
| CN1973878A (en) | Medicine for treating children's stomachache and its prepn | |
| CN1208082C (en) | Yunan red drug tablet , its preparation method and use | |
| CN1237454A (en) | Health-care medicine with therapeutic action of curing gastropathy and its preparation method | |
| CN1233364C (en) | Chinese medicine for treating digestive ulcerating sore and its preparation method | |
| CN1285367C (en) | Medicinal preparation for treating diabetes and its preparation method | |
| CN1299756C (en) | Stomach-benefiting medicine and its prepn | |
| CN1264563C (en) | Gastropathy treating medicine and its preparation | |
| CN1233416C (en) | Compound pepsin powder for treating child dyspepsia and its preparation method | |
| CN1506083A (en) | Gastrosis treating Chinese medicine powder and its usage | |
| CN1066956C (en) | Weitongxiao traditional Chinese medicine for curing gastro-duodenal ulcer and gastrorrhagia | |
| CN1183297A (en) | Katsutoxin pill for tumor and preparing method thereof | |
| CN1088365C (en) | Medicine for curing infectious gastrosis and its preparing process | |
| CN1236811C (en) | Medicine for curing gastropathy | |
| CN1943732A (en) | A medicinal composition for treatment of psoriasis | |
| CN1111419C (en) | A kind of medicine for the treatment of cardiovascular and cerebrovascular vessel apoplexy and premonitory apoplexy symptom and preparation method thereof | |
| CN1212151A (en) | Health-care products composition | |
| CN1277570C (en) | Pharmaceutical for treating alimentary tract ulcer disease and preparing process thereof | |
| CN1413673A (en) | Medicine for treating diabetes and its preparation method | |
| CN1465357A (en) | Chinese patent drug for treating chronic gastritis and chronic gastric ulcer | |
| CN1413640A (en) | Chinese medicine composition for treating enteritis | |
| CN1273174C (en) | Gastrosis treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |